Equities

Roquefort Therapeutics PLC

ROQ:LSE

Roquefort Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.20
  • Today's Change0.00 / 0.00%
  • Shares traded123.97k
  • 1 Year change-48.94%
  • Beta0.0650
Data delayed at least 20 minutes, as of Feb 06 2026 15:58 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Roquefort Therapeutics PLC had revenues fall -100.00% from 200.00k to 0.00, though the company grew net income from a loss of 1.74m to a smaller loss of 971.80k.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-15.04%
Return on equity-18.23%
Return on investment-17.23%
More ▼

Cash flow in GBPView more

In 2024, cash reserves at Roquefort Therapeutics PLC fell by 200.21k. Cash Flow from Financing totalled 584.92k or -- of revenues. In addition the company used 783.73k for operations while cash from investing was breakeven.
Cash flow per share-0.0063
Price/Cash flow per share--
Book value per share0.0302
Tangible book value per share0.0057
More ▼

Balance sheet in GBPView more

Roquefort Therapeutics PLC has a Debt to Total Capital ratio of 7.47%.
Current ratio2.80
Quick ratio--
Total debt/total equity0.0807
Total debt/total capital0.0747
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.